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Table  1
Minimum inhibitory concentrations (MICs) of fosfomycin and various carbapenems, duration of the post-antibiotic effect (PAE), frequency of mutation, results of syne
testing,  and frequency of various resistance mechanisms for fosfomycin and carbapenems alone and in combination for 70 clinical carbapenem-resistant Pseudomo
aeruginosa (CR-PA).
Antibiotic(s) MIC (g/mL) PAE (h) Mutation frequencya Percentage of
isolates showing
synergy (n)
Percentage of isolates positive for
carbapenem resistance mechanism (n)b
PAO1 CM06 SI19 CH35 UB45 MexAB MexXY OprD AmpC
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is-FOS 128 1 TNTC 3.1 × 10−9 2.1 × 10−10 2.7 × 10−11 3.2 × 10−9
Carbapenems
MEM 4 2 <2.9 × 10−9 <7.3 × 10−9 <3.3 × 10−9 <1.4 × 10−10 3.8 × 10−8
IPM 2 2 <2.9 × 10−9 TNTC TNTC <1.4 × 10−10 <5.2 × 10−9
DOR 2 2 <2.9 × 10−9 <7.3 × 10−9 2.4 × 10−9 <1.4 × 10−10 <5.2 × 10−9
Combinations
FOS + MEM 32/0.5 2 <2.9 × 10−9 6.8 × 10−8 2.4 × 10−9 <1.4 × 10−10 5.8 × 10−8 40.0 (28) 82.1 (23) 57.1 (16) 82.1 (23) 0 (0
FOS  + IPM 16/0.5 2 7.2 × 10−9 8.2 × 10−9 TNTC 4.4 × 10−10 1.9 × 10−8 38.6 (27) 96.3 (26) 70.4 (19) 88. 9 (24) 0 (0
FOS  + DOR 16/0.5 2 <2.9 × 10−9 7.9 × 10−9 3.6 × 10−9 <1.4 × 10−10 1.9 × 10−8 45.7 (32) 87.5 (28) 65.6 (21) 81.3 (26) 0 (0
FOS, fosfomycin; MEM,  meropenem; IPM, imipenem; DOR, doripenem; TNTC, too numerous to count.
a For selected clinical CR-PA strains (CM06, SI19, CH35 and UB45) and the standard strain PA01.
b Among isolates showing synergy.
CR-PA infection. Further in vivo studies should be performed on
combination efﬁcacy and pharmacokinetic aspects.
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Trimethoprim/sulfamethoxazole resistance in
clinical isolates of Burkholderia pseudomallei
from Thailand
Sir,
Burkholderia pseudomallei is the cause of melioidosis, a se
ous infection associated with a mortality rate of 14–43% [
Recommended antimicrobial therapy is ≥10 days of parente
ceftazidime or a carbapenem, followed by oral trimethopri
sulfamethoxazole (SXT; co-trimoxazole) to complete up to 
weeks of therapy [2]. A previous evaluation of 1976 clinical B. pse
domallei isolated from patients in northeast Thailand between 19
and 2003 reported that SXT resistance was  detected in 13% of is
lates [3]. Subsequent studies have reported much lower rates
SXT resistance for isolates from Laos (0.8%), Australia (0.4%) a
Cambodia (0%) [4]. Here we report the results of a re-evaluation
SXT resistance in Thailand. Second-line oral treatment in patien
infected with SXT-resistant B. pseudomallei or in whom SXT is co
traindicated is amoxicillin/clavulanic acid (AMC) [1], thus we al
evaluated the susceptibility of SXT-resistant isolates to AMC  a
doxycycline (DOX), which is used less frequently as an alternati
to SXT.
Susceptibility to SXT was  determined by Etest (bioMérieu
Marcy-l’Étoile, France) [3], with reading of the minimum inhibito
concentration (MIC) at the 80% inhibition point. Interpretative sta
dards for the Etest were based on Clinical and Laboratory Standar
Institute (CLSI) guidelines for broth microdilution, which classiﬁ
SXT MICs of ≤2/38 mg/L as susceptible and ≥4/76 mg/L as resUniversity, 447 Sri Ayudthaya Road, Rajathevi, Bangkok 10400,
Thailand
Preecha Montakantikul
Department of Pharmacy, Faculty of Pharmacy, Mahidol University,
447 Sri Ayudthaya Road, Rajathevi, Bangkok 10400, Thailand
Mullika Traidej Chomnawang ∗tant [5]. Escherichia coli ATCC 25922 was  used as the control. For
SXT-resistant isolates, the Etest was  used to deﬁne susceptibility to
trimethoprim (TMP) alone and sulfamethoxazole (SMX) alone. Sus-
ceptibility testing to AMC  and DOX was also performed using the
Etest, in which the MIC  was read at the point of no visible growth.
Escherichia coli ATCC 35218 was used as a control for AMC, and E. coli
ATCC 25922 was used as a control for TMP, SMX  and DOX.
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Mootsikapun P, et al. Trimethoprim–sulfamethoxazole versus trimethoprim–
sulfamethoxazole plus doxycycline as oral eradicative treatment for melioidosis
(MERTH): a multicentre, double-blind, non-inferiority, randomised controlled
trial. Lancet 2014;383:807–14.
[3] Wuthiekanun V, Cheng AC, Chierakul W,  Amornchai P, Limmathurotsakul
D,  Chaowagul W,  et al. Trimethoprim/sulfamethoxazole resistance in clini- Letters to the Editor / International Journal o
 1. Trimethoprim/sulfamethoxazole minimum inhibitory concentrations (MICs) fo
 hospital in northeast Thailand between 2004 and 2012. MICs were determined usi
corresponding MIC. The table shows the total and annual number of B. pseudomalle
percentage resistant.
Two isolate collections were evaluated. The ﬁrst was drawn
 a retrospective study of 3270 patients with culture-proven
lioidosis at Sappasithiprasong Hospital in northeast Thailand
ween 2004 and 2012. A single isolate was used per patient
e ﬁrst positive culture). All isolates had been stored at −80 ◦C
 subculture recovered isolates from 3038 patients. The Etest
 MIC  ranged from 0.016 mg/L to ≥32 mg/L [MIC50 (concentra-
 that inhibits 50% of bacterial isolates) = 0.19 mg/L and MIC90
ncentration that inhibits 90% of bacterial isolates) = 0.75 mg/L;
rquartile range 0.094–0.25 mg/L] (Fig. 1). Ten isolates (0.33%)
re resistant to SXT, with an annual resistance rate ranging from
to 0.7%. As this is considerably lower than that reported by us
viously for B. pseudomallei isolated from patients presenting to
 same hospital between 1992 and 2003 [3], we re-evaluated this
inal collection. Previously, 258/1976 isolates were assigned as
-resistant based on the Etest [3], of which 255 could be recov-
d from frozen stocks. Etest could only conﬁrm SXT resistance in
(5.1%) of these 255 isolates (Supplementary Table S1). The 23
-resistant isolates from both collections were resistant to TMP
 SMX  when tested as separate agents (Supplementary Table
. All SXT-resistant isolates were susceptible to AMC, but only
isolates (91%) were susceptible to DOX.
The CLSI recommends the broth microdilution method as the
dard method for MIC  testing of B. pseudomallei [5]. This is
ractical for such a large study collection and was therefore used
erify Etest results for a subset of isolates. These were all 13
ates from the 1992–2003 collection that were classiﬁed as resis-
t in both studies as well as 15 randomly selected isolates from
 1992–2003 collection with discrepant results between the two
dies. Escherichia coli ATCC 25922 was used as the control. This
onstrated complete concordance of results between broth dilu-
 and Etest performed in this study, conﬁrming that the previous
dy had overestimated resistance. The most likely explanation for
 erroneous results in the original study is error in reading the 80%
ibition point. This is inherently subjective and a minor difference
he interpretation of MIC  results that are close to the breakpoint
 lead to false classiﬁcation as resistance. The majority (68%) of
s for isolates that were erroneously deﬁned as resistant in the
vious study were 3 mg/L or 4 mg/L, which is consistent with a
or upshift in the MIC  value but a large error in susceptibility
siﬁcation [3]. Inhibition zones frequently have diffuse edges,
[4] icrobial Agents 45 (2015) 550–561
holderia pseudomallei from 3038 patients with primary melioidosis presenting
 Etest. The numbers above each column represent the number of isolates with
tes tested, the MIC50 (concentration that inhibits 50% of bacterial isolates) and
 reading against a black background aided technical observation
his study.
Our ﬁnding that 99.7% of clinical B. pseudomallei isolates were
ceptible to SXT is comparable with rates reported from Laos
.2%), Australia (99.6%) and Cambodia (100%) [4], which indi-
e that primary SXT resistance in B. pseudomallei is uncommon.
r study also conﬁrmed that SXT-resistant B. pseudomallei were
ceptible to AMC, the current second-line drug of choice.
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Changing antimicrobial resistance patterns and
trends of Shigella isolates in Ningbo, mid-east
China, 2005–2013
Sir
Presently, the increase in antimicrobial-resistant Shigella iso-
lates has been greatly crippling the treatment of shigellosis. Due to
the great variations in antimicrobial resistance patterns of Shigella,
monitoring antimicrobial resistance of these micro-organisms is
necessary to aid in the selection of appropriate antimicrobials.
This study included 226 clinical Shigella isolates (1.1%) recovered
from a total of 21,500 outpatients with diarrhoea during two
time periods (2005–2007 and 2010–2013) in Ningbo, mid-east
China. All isolates were identiﬁed according to biochemical char-
acteristics and serotyping. Antimicrobial susceptibility testing was
conducted by the disc diffusion method according to Clinical and
Laboratory Standards Institute (CLSI) guidelines [1] using the fol-
lowing antimicrobial disks (Oxoid Ltd., Basingstoke, UK): ampicillin
(10 g); cefotaxime (30 g); aztreonam (10 g); ciproﬂoxacin
(5 g); gentamicin (10 g); and trimethoprim/sulfamethoxazole
(SXT) (1.25/23.75 g). Antimicrobial susceptibility testing results
were interpreted according to CLSI guidelines [2]. Strains resistant
to three or more drugs of chemically unrelated classes were deﬁned
as multidrug-resistant [3].
Overall, the proportion of strains resistant was 83.2% for ampi-
cillin, 72.6% for SXT, 47.8% for cefotaxime, 44.2% for ciproﬂoxacin,
38.9% for aztreonam and 28.3% for aztreonam (Table 1). All isolates
resistant to cefotaxime were positive for extended-spectrum -
lactamase (ESBL). The rates of multidrug resistance and resistance
to all six antimicrobials tested were 53.1% and 10.6%, respectively.
Comparison between the two  time periods (2005–2007 and
2010–2013) showed signiﬁcant increases in the resistance preva-
lence to cefotaxime (32.8–67.3%; P < 0.01), gentamicin (17.2–42.9%;
P < 0.01) and aztreonam (20.3–63.3%; P < 0.01) as well as a
minor increase in resistance to ampicillin (78.1–89.8%; P = 0.02),
whereas there were no signiﬁcant changes in resistance rates to
ciproﬂoxacin (40.6–49.0%; P > 0.05) and SXT (71.9–73.5%; P > 0.05).
In particular, obvious upward trends were seen in the prevalence
of multidrug resistance (39.1–71.4%; P < 0.01) and resistance to all
six antimicrobials tested (3.1–20.4%; P < 0.01) (Table 1). In addi-
tion, the top three most predominant resistance patterns accounted
for 55.1% of 98 isolates during 2010–2013, which was  statistically
greater than the 38.3% of 128 isolates during 2005–2007 (P < 0.01),
showing a clustering trend in resistance patterns for recent years.
These ﬁndings also showed certain inconsistency with resis-
tance data in the National Antimicrobial Resistance Monitoring
System for Enteric Bacteria (NARMS) released by the US Centres for
Disease Control and Prevention (CDC) for the following drugs [4]:
ciproﬂoxacin (44.2% in this study vs. 2% in NARMS); cefotaxime
(47.8% in this study vs. 1.1% in NARMS); and a minor increase in
ampicillin resistance in this study compared with a downward
trend in NARMS (from 70.7% in 2005 to 25.5% in 2012).
In summary, the present study demonstrated the rapid spread of
antibiotic-resistant Shigella strains in recent years, posing a serious
challenge because the treatment of this disease depends greatly on
timely and effective use of antimicrobials.
Funding: This study was  funded by Ningbo Municipal Key Sci-
entiﬁc And Technological Innovation Team Plan [No. 2012B82018]
Table 1
Prevalence of antimicrobial-resistant Shigella isolates and multidrug-resistant (MDR) strains during two  periods, 2005–2007 and 2010–2013.
Antimicrobial agent No. (%) of resistant isolates P-value (2) between two periods Total 2005–2013 (n = 226)
2005–2007 (n = 128) 2010–2013 (n = 98)
Ampicillin 100 (78.1) 88 (89.8) <0.05 (5.40) 188 (83.2)
Cefotaxime 42 (32.8) 66 (67.3) <0.01 (26.53) 108 (47.8)
Aztreonam 26 (20.3) 62 (63.3) <0.01 (43.06) 88 (38.9)
Gentamicin 22 (17.2) 42 (42.9) <0.01 (18.02) 64 (28.3)
Ciproﬂoxacin 52 (40.6) 48 (49.0) >0.05 (1.57) 100 (44.2)
SXT  92 (71.9) 72 (73.5) >0.05 (1.21) 164 (72.6)
All  six antimicrobials tested 4 (3.1) 20 (20.4) <0.01 (29.42) 24 (10.6)
MDRa 50 (39.1) 70 (71.4) <0.01 (23.34) 120 (53.1)
SXT, trimethoprim/sulfamethoxazole.
a Strains resistant to three or more drugs of chemically unrelated classes were deﬁned as MDR  [3].
